NCT03050541

Brief Summary

The purpose of this study is to examine the effects of MDMA on encoding and retrieval of emotional and social memories in healthy young adults. The study will explore the effects on memory retrieval when the drug is administered 1) before encoding, and 2) before retrieval.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Dec 2014

Typical duration for not_applicable healthy

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2014

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

December 18, 2014

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
6 months until next milestone

First Posted

Study publicly available on registry

February 13, 2017

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

June 29, 2018

Completed
Last Updated

June 29, 2018

Status Verified

May 1, 2018

Enrollment Period

1.8 years

First QC Date

December 18, 2014

Results QC Date

June 7, 2017

Last Update Submit

May 30, 2018

Conditions

Keywords

MDMAadult

Outcome Measures

Primary Outcomes (1)

  • Probability of Accurately Recalling Visual Stimuli

    During encoding, participants were presented with labels that were sometimes followed by pictures. During the first memory test, participant were presented again with all of the labels and asked, "Did you see this picture?" Hit and false alarm rates were then calculated, and memory accuracy was measured by hits minus false alarms.

    90 minutes into Session 2

Secondary Outcomes (1)

  • Probability of Accurately Recognizing Visual Stimuli

    90 minutes into Session 2

Study Arms (3)

MDMA at Memory Encoding

EXPERIMENTAL

20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.

Drug: MDMADrug: Placebo

MDMA at Memory Retrieval

EXPERIMENTAL

20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..

Drug: MDMADrug: Placebo

Placebo at both sessions

PLACEBO COMPARATOR

20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.

Drug: Placebo

Interventions

MDMADRUG

This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.

MDMA at Memory EncodingMDMA at Memory Retrieval
MDMA at Memory EncodingMDMA at Memory RetrievalPlacebo at both sessions

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Normal healthy males and females, aged 18-40 years.

You may not qualify if:

  • any current medical condition requiring medication or abnormal electrocardiogram
  • current or past medical condition considered to be a contraindication for the study conditions
  • any current Axis I psychiatric disorder (APA, 1994) including Substance Use Disorder, or Anxiety Disorder or Major Depression in the past year, any history of psychosis
  • less than high school education
  • lack of fluency in English
  • night shift work
  • pregnancy, lactation, or plans to become pregnant
  • use of hormonal contraception

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

N-Methyl-3,4-methylenedioxyamphetamine

Intervention Hierarchy (Ancestors)

AmphetaminesPhenethylaminesEthylaminesAminesOrganic Chemicals

Results Point of Contact

Title
Office of Clinical Research
Organization
University of Chicago

Study Officials

  • Harriet de Wit, PhD

    University of Chicago

    PRINCIPAL INVESTIGATOR
  • David Gallo, PhD

    University of Chicago

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2014

First Posted

February 13, 2017

Study Start

December 1, 2014

Primary Completion

September 1, 2016

Study Completion

September 1, 2016

Last Updated

June 29, 2018

Results First Posted

June 29, 2018

Record last verified: 2018-05